Danirixin

Class: CXCR2 antagonist

Spectrum of activity:	Gram-positive
Details of activity:	Developed for the treatment of COPD and influenza-exacerbated, neutrophil-mediated respiratory tract dysfunction
Description:	Johnson. M., Wilfret. D., Chen. S., Jones. L., Bloomer. J., Peat. A."First Time Single and Repeated Dose IV Administration and Absolute Bioavailability of a Novel CXCR2 Antagonist, GSK1325756 (Danirixin); Study NCT02169583 " Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy. 2015.
Institute where first reported:	University of Oxford
Year first mentioned:	2015
Highest developmental phase:	Phase 2
Development status:	Active

Chemical structure(s):
Canonical SMILES:	CC1=C(C=CC=C1F)NC(=O)NC2=CC=C(C(=C2O)S(=O)(=O)[C@H]3CCCNC3)Cl
Isomeric SMILES:	CC1=C(C=CC=C1F)NC(=O)NC2=C(C(=C(C=C2)Cl)S(=O)(=O)[C@H]3CCCNC3)O
InChI:	InChI=1S/C19H21ClFN3O4S/c1-11-14(21)5-2-6-15(11)23-19(26)24-16-8-7-13(20)18(17(16)25)29(27,28)12-4-3-9-22-10-12/h2,5-8,12,22,25H,3-4,9-10H2,1H3,(H2,23,24,26)/t12-/m0/s1
InChI Key:	NGYNBSHYFOFVLS-LBPRGKRZSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/24780598

External links:
Guide to Pharmacology:	danirixin
Main Source:	http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3798&sKey=066fe91c-1dff-48d2-a97e-9d682ce3a71c&cKey=5a48a0eb-1801-496a-bb53-c05aea08f54a&mKey=7a574a80-eab1-4b50-b343-4695df14907e